Gefitinib (Figure 2), an epidermal growth factor receptor (EGFR) inhibitor with quinazolinamine moiety, was reported to inhibit BCRP [6] but also modulate the function of P-gp in multidrug-resistant cancer cells [7]. Here, EGFR is linked to cancer.